))
Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of May 20, 2024
Manage episode 419857686 series 3560281
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more. Read the full coverage here:
Difficult-to-treat psoriatic arthritis 'not all about the therapies'
Samsung biosimilar comparable to etanercept for psoriatic arthritis outcomes at 1 year
Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access
VIDEO: Mitigating risk for psoriatic arthritis in patients with psoriasis
FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo
References:
Healio Interview
Łosińska K, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25345.
Ogdie-Beatty A. Psoriatic Arthritis in 2024. Presented at The Congress of Clinical Rheumatology East; May 9-12, 2024; Destin, Florida (hybrid meeting).
114 episodes
Share
